相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Molecular Mechanism for the Allosteric Inhibition of the Human Serotonin Transporter by Antidepressant Escitalopram
Weiwei Xue et al.
ACS CHEMICAL NEUROSCIENCE (2022)
Captured snapshots of PARP1 in the active state reveal the mechanics of PARP1 allostery
Elise Rouleau-Turcotte et al.
MOLECULAR CELL (2022)
Discovery of novel anti-tumor compounds targeting PARP-1 with induction of autophagy through in silico and in vitro screening
Danfeng Shi et al.
FRONTIERS IN PHARMACOLOGY (2022)
Selectively targeting individual bromodomain: Drug discovery and molecular mechanisms
Qianqian Wang et al.
PHARMACOLOGICAL RESEARCH (2021)
Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases
Komal Thapa et al.
LIFE SCIENCES (2021)
Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition
Tom E. H. Ogden et al.
NUCLEIC ACIDS RESEARCH (2021)
Rapid Detection and Signaling of DNA Damage by PARP-1
Nootan Pandey et al.
TRENDS IN BIOCHEMICAL SCIENCES (2021)
PARP1: Structural insights and pharmacological targets for inhibition
Jacob O. Spiegel et al.
DNA REPAIR (2021)
Molecular Mechanism of Ca2+in the Allosteric Regulation of Human Parathyroid Hormone Receptor-1
Mengrong Li et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
Exploring the thermodynamic, kinetic and inhibitory mechanisms of 5-iTU targeting mitotic kinase haspin by integrated molecular dynamics
Qianqian Wang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2021)
Subtype-selective mechanisms of negative allosteric modulators binding to group I metabotropic glutamate receptors
Ting-ting Fu et al.
ACTA PHARMACOLOGICA SINICA (2021)
Compound C620-0696, a new potent inhibitor targeting BPTF, the chromatin-remodeling factor in non-small-cell lung cancer
Jiahui Xu et al.
FRONTIERS OF MEDICINE (2020)
Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models
Janice M. Santiago-O'Farrill et al.
CANCER (2020)
ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum Mechanics Energy Surfaces in Solution
Chuan Tian et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2020)
Structural basis for allosteric PARP-1 retention on DNA breaks
Levani Zandarashvili et al.
SCIENCE (2020)
The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction
Yue Zhao et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design
Ercheng Wang et al.
CHEMICAL REVIEWS (2019)
Refined Empirical Force Field to Model Protein-Self-Assembled Monolayer Interactions Based on AMBER14 and GAFF
Pratiti Bhadra et al.
LANGMUIR (2019)
Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: Design, synthesis and antitumor activity evaluation
Ahmed T. A. Boraei et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update
Priyancy G. Jain et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders
Robert J. Henning et al.
CARDIOVASCULAR TOXICOLOGY (2018)
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy
Gwynn Ison et al.
CLINICAL CANCER RESEARCH (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Targeting NAD(+) degradation: The therapeutic potential of flavonoids for Alzheimer's disease and cognitive frailty
Qingwei Ruan et al.
PHARMACOLOGICAL RESEARCH (2018)
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases
Nathan A. Berger et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors
Ann-Gerd Thorsell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Rebecca Gupte et al.
GENES & DEVELOPMENT (2017)
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer
Martin Reck et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
Pepijn M. Schoonen et al.
NATURE COMMUNICATIONS (2017)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman et al.
GYNECOLOGIC ONCOLOGY (2015)
Gaussian Accelerated Molecular Dynamics: Unconstrained Enhanced Sampling and Free Energy Calculation
Yinglong Miao et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
PyEMMA 2: A Software Package for Estimation, Validation, and Analysis of Markov Models
Martin K. Scherer et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
Clare L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PARP-1 Activation Requires Local Unfolding of an Autoinhibitory Domain
Jennine M. Dawicki-McKenna et al.
MOLECULAR CELL (2015)
Investigating the allosteric reverse signalling of PARP inhibitors with microsecond molecular dynamic simulations and fluorescence anisotropy
Jean-Remy Marchand et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2014)
Markov state models of biomolecular conformational dynamics
John D. Chodera et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2014)
Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set
Huiyong Sun et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2014)
ARTD1/PARP1 Negatively Regulates Glycolysis by Inhibiting Hexokinase 1 Independent of NAD+ Depletion
Elise Fouquerel et al.
CELL REPORTS (2014)
Slow dynamics of a protein backbone in molecular dynamics simulation revealed by time-structure based independent component analysis
Yusuke Naritomi et al.
JOURNAL OF CHEMICAL PHYSICS (2013)
Structural Basis for DNA Damage-Dependent Poly(ADP-ribosyl)ation by Human PARP-1
Marie-France Langelier et al.
SCIENCE (2012)
Markov models of molecular kinetics: Generation and validation
Jan-Hendrik Prinz et al.
JOURNAL OF CHEMICAL PHYSICS (2011)
Probing molecular kinetics with Markov models: metastable states, transition pathways and spectroscopic observables
Jan-Hendrik Prinz et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2011)
Toward a unified nomenclature for mammalian ADP-ribosyltransferases
Michael O. Hottiger et al.
TRENDS IN BIOCHEMICAL SCIENCES (2010)
Robust Perron cluster analysis in conformation dynamics
P Deuflhard et al.
LINEAR ALGEBRA AND ITS APPLICATIONS (2005)